Archive for November 8th, 2017

Equities First Holdings Has Offices Around The Globe11.08.17

Equities First Holdings has a lot of offices around the world that will help people in places like the UK, Australia, South Africa, and New Zealand. This company knows that they can give their customers all the help they need from these offices, and they tailor all their work to the people who live in that area. Some one who comes in in Australia gets a loan that will work for the market there, and there are people who come to offices in the UK who get loans that are made just for that place. It is much easier for someone to get the exact sort of loan they need, and they are much more comfortable because they have taken out a loan with someone in an office that is near them. The customer service is amazing, and the company will always be there to help customers get more loans if they need.

 

Posted in Equities First, Loanwith No Comments →

Clay Siegall Redefines Cancer Treatment and Therapies11.08.17

A finalist in the healthcare category of the Ernest and young Pacific Northwest Entrepreneur of the year awards, Dr. Clay Siegall is a winner of the Pierce Awards (1995). He holds a PhD. (Genetics) from George Washington University and a Bachelors of Science degree in Zoology from the University of Maryland.

Background

Dr. Siegall co-founded Seattle Genetics Inc. and has been its chairman since 2004. He has been C.E.O for 15 years and president for 17 years. His experience in the field of research on Cancer and development of therapeutic drugs stretches 20 years. Prior to that, he was executive Vice president for 3 years and Chief Scientific Officer for 5 years (1997-2002). He was also the institutes Principal Scientist from1995-1997. At Ultragenyx Pharmaceutical Inc. Dr. Siegall has been chairman since 2014.

Contribution

Apart from these, he has been director for the past 12 years at Alder Biopharmaceuticals and serves on the Board of Governors at the Hutchison Cancer Research Business Alliance and director of Washington Biotech and Biomedicine Association.From 2013-2016, Dr. Siegall was the non- executivedirector at Mirna Therapeutics Inc. and a further three years between 1988-1991 as staff and biotechnology employee. Clay Siegall has vastly contributed to the development and manufacture of many useful drugs in many ways. His works cannot be matched to any other scientists’ as he harbors special skills in research.

Leadership roles

When not holding managerial positions in different institutions or pharmaceutical companies, Dr. Clay Siegall authors scientific papers and journals, having authored 67 papers so far. He also has nine different patents to his name. Dr. Clay Siegall sits on the editorial boards of three different scientific journals and also in the board of Scientific Counselors to the Treatment Research Foundation. Dr. Siegall has led his company to profitability with strategic licensing of its Antibody Drugs Conjugates (ADC) technology generating over $350 million and the company has generated over $1.2 billion from private and public financial deals.

Conclusion

Clay Siegall is instrumental in the world of finding treatment methods in addition to therapies. He has mastered the art of using science to locate the connection between diseases and cells. What is more, Clay Siegall has a deep understanding of how diseases can be treated by understanding their genetic mutation. That is why he continues to be applauded for his input in the industry of medicine. For Clay, the treatment lies in understanding some of the basic knowledge associated with cell biology.

Posted in Sciencewith No Comments →

  • You Avatar